Company Overview and News
Goldphyre Resources Ltd's (ASX:GPH) shares are in pre-open this morning, following the ASX granting the company a trading halt. Goldphyre requested the halt pending details regarding the underwriting of the listed options series GPHO, which are exercisable at $0.08 and expire on 30 September 2016. Shares in the company last traded at $0.098, and recently hit $0.14 per share. The halt will remain in place until the opening of trade on Thursday 25th August 2016, or earlier if an announcement is made to the market.
Goldphyre Resources Ltd (ASX:GPH) has been granted a trading halt by the ASX, pending an update on a JORC Resource. Goldphyre recently received the final assays from the Lake Wells Potash Project, located in Western Australia. The company has previously outlined that it expected to deliver a JORC Resource in June 2016. The halt will remain in place until the opening of trade on Wednesday 29th June 2016, or earlier if an announcement is made to the market.
Goldphyre Resources Ltd (ASX:GPH) aims to supply sulphate of potash (SOP) into the domestic market where Australia currently imports 100% of its potassium fertiliser requirements. An exploration target has been estimated at its Lake Wells Potash Project in Western Australia which provides a basis for its objective of producing 75,000 - 100,000 tonne-a-year sulphate of potash (brine). Lake Wells has been identified as a high-grade SOP brine salt lake, confirmed both at the salt lake surface and at depth.
2018-05-25 - Asif
Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...
2018-05-25 - Asif
Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...
2018-05-21 - Asif
Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...